期刊文献+

新辅助化疗、肿瘤细胞减灭术、手术后化疗(腹腔热灌注)对晚期卵巢癌的疗效分析 被引量:7

下载PDF
导出
摘要 目的:观察新辅助化疗、肿瘤细胞减灭术和腹腔热灌注联合使用治疗晚期卵巢癌的效果。方法:从我院2017年2月~2018年1月接治的晚期卵巢癌患者中,随机抽取64例,将其分为研究组和参照组。对参照组中的32例采用常规治疗,对研究组中的32例采取新辅助化疗联合肿瘤细胞减灭术以及术后腹腔热灌注进行治疗。2个月后,观察两组临床治疗效果。结果:研究组在手术时间、术中出血量、术后住院时间、临床总有效率、术后复发率和死亡率方面远远优于参照组。结论:对晚期卵巢癌采用新辅助化疗联合肿瘤细胞减灭术以及腹腔热灌注进行治疗,具有良好的治疗效果,可以促进康复,可在临床上推广。
出处 《北方药学》 2018年第11期42-43,共2页 Journal of North Pharmacy
  • 相关文献

参考文献5

二级参考文献69

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2Chang S J, Bristow RE, Ryu HS. Impact of complete cytoreduction leav- ing no gross residual disease associated with radical cytoreduetive surgical procedures on survival in advanced ovarian cancer [ J ]. Ann Surg On- col, 2012, 19 (13): 4059-4067.
  • 3Chereau E, Lavoue V, Ballester M, et al. External validation of a lapa- roscopie - based score to evaluate respectability for patients with ad- vanced ovarian cancer undergoing interval debulking surgery E J ]. Anti- cancer Res, 2011, 31 (12) : 4469 -4474.
  • 4Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky ad- vanced stage ovarian, tubal, and peritoneal carcinoma treated with pri- mary debulking surgery (PDS) during an identical time period as the randomized EORTC - NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) [J]. Gyneeol Oncol, 2012, 124 (1): 10-14.
  • 5Dewdney SB, Rimel B J, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer : survey results from members of the society of gynecologic oncolo- gists [J]. Gynecol Oncol, 2010, 119 (1): 18-21.
  • 6Fags - Olsen CL, Hgtkansson F, Antonsen SL, et al. Diagnostic accu- racy of risk of malignancy index in predicting complete tumor removal at primary dehulking surgery-for ovarian cancer patients [ J]. Acta Obstet Gynecol Scand, 2013, 92 (6): 721-726.
  • 7Freedman OC, Dodge J, Shaw P, et al. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy [ J ]. Gynecol Oncol, 2010, 119 (1): 22-25.
  • 8Vergote I, Trop6 CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage ~[C or 1V ovarian cancer [J]. N Engl J Med, 2010, 363 (10): 943-953.
  • 9Furukawa N, Sasaki Y, Shigemitsu A, et al. CA - 125 cut - off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer [ J ]. J Gynecol Oncol, 2013, 24 (2): 141-145.
  • 10Keyver - Paik MD, Zivanovic O, Rudlowski C, et al. Interval debulk- ing surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage RIC and 1V ovarian cancer [J]. Onkologie, 2013, 36 (6) : 324 -332.

共引文献129

同被引文献64

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部